These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22235305)

  • 1. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
    Manfè V; Biskup E; Rosbjerg A; Kamstrup M; Skov AG; Lerche CM; Lauenborg BT; Odum N; Gniadecki R
    PLoS One; 2012; 7(1):e29541. PubMed ID: 22235305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
    Biskup E; Kamstrup MR; Manfé V; Gniadecki R
    Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.
    Wei T; Biskup E; Gjerdrum LM; Niazi O; Ødum N; Gniadecki R
    Oncotarget; 2016 Jul; 7(30):48391-48400. PubMed ID: 27351221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1-STAT1 pathway.
    Liszewski W; Naym DG; Biskup E; Gniadecki R
    Photodermatol Photoimmunol Photomed; 2017 May; 33(3):164-171. PubMed ID: 28196286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
    García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
    McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
    J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
    Sors A; Jean-Louis F; Pellet C; Laroche L; Dubertret L; Courtois G; Bachelez H; Michel L
    Blood; 2006 Mar; 107(6):2354-63. PubMed ID: 16219794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
    Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
    Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
    Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
    Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
    Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
    Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
    Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
    J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
    Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
    Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
    Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
    Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
    Nihal M; Ahmad N; Wood GS
    Cell Cycle; 2014; 13(4):632-40. PubMed ID: 24343700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.